Survival rates of familial and sporadic prostate cancer patients

Aim: To compare cancer-specific survival rates for familial and sporadic prostate cancer patients. Materials and Methods: Gleason score and age at diagnosis of familial group and sporadic group were compared by χ² and t-test. Cancer-specific survival rates were analyzed by the Kaplan — Meier method...

Full description

Saved in:
Bibliographic Details
Published in:Experimental Oncology
Date:2015
Main Authors: Plonis, J., Nakazawa-Miklasevica, M., Malevskis, A., Vaganovs, P., Pildava, S., Vjaters, E., Gardovskis, J., Miklasevics, E.
Format: Article
Language:English
Published: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2015
Subjects:
Online Access:https://nasplib.isofts.kiev.ua/handle/123456789/145473
Tags: Add Tag
No Tags, Be the first to tag this record!
Journal Title:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Cite this:Survival rates of familial and sporadic prostate cancer patients / J. Plonis, M. Nakazawa-Miklasevica, A. Malevskis, P. Vaganovs, S. Pildava, E. Vjaters, J. Gardovskis, E. Miklasevics // Experimental Oncology. — 2015. — Т. 37, № 2. — С. 154-155. — Бібліогр.: 12 назв. — англ.

Institution

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id nasplib_isofts_kiev_ua-123456789-145473
record_format dspace
spelling Plonis, J.
Nakazawa-Miklasevica, M.
Malevskis, A.
Vaganovs, P.
Pildava, S.
Vjaters, E.
Gardovskis, J.
Miklasevics, E.
2019-01-22T11:44:59Z
2019-01-22T11:44:59Z
2015
Survival rates of familial and sporadic prostate cancer patients / J. Plonis, M. Nakazawa-Miklasevica, A. Malevskis, P. Vaganovs, S. Pildava, E. Vjaters, J. Gardovskis, E. Miklasevics // Experimental Oncology. — 2015. — Т. 37, № 2. — С. 154-155. — Бібліогр.: 12 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/145473
Aim: To compare cancer-specific survival rates for familial and sporadic prostate cancer patients. Materials and Methods: Gleason score and age at diagnosis of familial group and sporadic group were compared by χ² and t-test. Cancer-specific survival rates were analyzed by the Kaplan — Meier method and compared by log-rank test. Statistically significant level was set at p < 0.05. Results: Among 1175 prostate cancer patients, familial group consisted of 215 (18.3%) patients, the sporadic group consisted of 960 (81.7%) patients. The familial group patient’s mean age at diagnosis (58.9 years old, 95% confidence interval (CI) 57.8–60.1) was significantly younger than that of sporadic group patients (67.2 years old, 95% CI 66.7–67.6) (p < 0.0001). Comparing Gleason score between familial group and sporadic group revealed no statistically significant difference. The analysis showed that 92% (95% CI 0.88–0.97) of familial group patients had a 10-year cancer-specific survival rates, which was a significantly better outcome than that of sporadic group with 69% (95% CI 0.60–0.78) 10-year cancer-specific survival rates (p = 0.0237). Conclusion: The study data demonstrate statistically significant difference between familial group and sporadic group concerning age and cancer-specific survival rates, but not Gleason score. Key Words: prostate cancer, hereditary, familial, survival rates.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Short communications
Survival rates of familial and sporadic prostate cancer patients
Article
published earlier
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
title Survival rates of familial and sporadic prostate cancer patients
spellingShingle Survival rates of familial and sporadic prostate cancer patients
Plonis, J.
Nakazawa-Miklasevica, M.
Malevskis, A.
Vaganovs, P.
Pildava, S.
Vjaters, E.
Gardovskis, J.
Miklasevics, E.
Short communications
title_short Survival rates of familial and sporadic prostate cancer patients
title_full Survival rates of familial and sporadic prostate cancer patients
title_fullStr Survival rates of familial and sporadic prostate cancer patients
title_full_unstemmed Survival rates of familial and sporadic prostate cancer patients
title_sort survival rates of familial and sporadic prostate cancer patients
author Plonis, J.
Nakazawa-Miklasevica, M.
Malevskis, A.
Vaganovs, P.
Pildava, S.
Vjaters, E.
Gardovskis, J.
Miklasevics, E.
author_facet Plonis, J.
Nakazawa-Miklasevica, M.
Malevskis, A.
Vaganovs, P.
Pildava, S.
Vjaters, E.
Gardovskis, J.
Miklasevics, E.
topic Short communications
topic_facet Short communications
publishDate 2015
language English
container_title Experimental Oncology
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
format Article
description Aim: To compare cancer-specific survival rates for familial and sporadic prostate cancer patients. Materials and Methods: Gleason score and age at diagnosis of familial group and sporadic group were compared by χ² and t-test. Cancer-specific survival rates were analyzed by the Kaplan — Meier method and compared by log-rank test. Statistically significant level was set at p < 0.05. Results: Among 1175 prostate cancer patients, familial group consisted of 215 (18.3%) patients, the sporadic group consisted of 960 (81.7%) patients. The familial group patient’s mean age at diagnosis (58.9 years old, 95% confidence interval (CI) 57.8–60.1) was significantly younger than that of sporadic group patients (67.2 years old, 95% CI 66.7–67.6) (p < 0.0001). Comparing Gleason score between familial group and sporadic group revealed no statistically significant difference. The analysis showed that 92% (95% CI 0.88–0.97) of familial group patients had a 10-year cancer-specific survival rates, which was a significantly better outcome than that of sporadic group with 69% (95% CI 0.60–0.78) 10-year cancer-specific survival rates (p = 0.0237). Conclusion: The study data demonstrate statistically significant difference between familial group and sporadic group concerning age and cancer-specific survival rates, but not Gleason score. Key Words: prostate cancer, hereditary, familial, survival rates.
issn 1812-9269
url https://nasplib.isofts.kiev.ua/handle/123456789/145473
citation_txt Survival rates of familial and sporadic prostate cancer patients / J. Plonis, M. Nakazawa-Miklasevica, A. Malevskis, P. Vaganovs, S. Pildava, E. Vjaters, J. Gardovskis, E. Miklasevics // Experimental Oncology. — 2015. — Т. 37, № 2. — С. 154-155. — Бібліогр.: 12 назв. — англ.
work_keys_str_mv AT plonisj survivalratesoffamilialandsporadicprostatecancerpatients
AT nakazawamiklasevicam survivalratesoffamilialandsporadicprostatecancerpatients
AT malevskisa survivalratesoffamilialandsporadicprostatecancerpatients
AT vaganovsp survivalratesoffamilialandsporadicprostatecancerpatients
AT pildavas survivalratesoffamilialandsporadicprostatecancerpatients
AT vjaterse survivalratesoffamilialandsporadicprostatecancerpatients
AT gardovskisj survivalratesoffamilialandsporadicprostatecancerpatients
AT miklasevicse survivalratesoffamilialandsporadicprostatecancerpatients
first_indexed 2025-12-07T16:09:55Z
last_indexed 2025-12-07T16:09:55Z
_version_ 1850866448870670336